Why Bausch + Lomb IPO is worth a look

This well-established company with a global presence may be the second-largest IPO this year.

Bausch + Lomb is the eyecare division of the Canadian Bausch Health Companies. Even though it’s only a part of a larger company, it employs more than 12,000 people globally. Bausch’s main headquarters is also in Canada but it has a US office in New Jersey.
In a year with fewer IPOs, Bausch + Lomb, due out this week, is the one to keep an eye out for because it’s a well-established and profitable company.

Bausch + Lomb starts trading on Friday

The company plans to sell 35 million shares at $21 to $24 each. If the market reaches the top of the price, Bausch could raise as much as $840 million. This could make it the year’s second-biggest IPO.
Bausch will price its deal on Thursday, May 5, and trade the next day on Nasdaq under the BLCO ticker symbol.

Bausch + Lomb is a well-established global company

Founded in 1853, Bausch + Lomb offers more than 400 eye health products, including contact lenses, lens care products, eyecare products, pharmaceuticals, over-the-counter products and surgical devices and instruments.

The company sells its products in more than 100 countries. Because of its global presence, in 2021 the company had a $3.76 billion revenue with $182 million in net earnings.
Learn how to buy Bausch + Lomb in our dedicated guide.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.